Cécile Campos1, Antoine Perrey2, Céline Lambert3, Bruno Pereira3, Marion Goutte1,4, Anne Dubois5, Felix Goutorbe1, Michel Dapoigny1, Gilles Bommelaer1,4, Constance Hordonneau2, Anthony Buisson6,7. 1. Service d'Hépato-Gastro Entérologie, Inserm, 3iHP, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France. 2. Service de Radiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France. 3. Unité de Biostatistiques, DRCI, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France. 4. M2iSH, Inserm U1071, 3iHP, USC-INRA 2018, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. 5. Service de Chirurgie Digestive, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France. 6. Service d'Hépato-Gastro Entérologie, Inserm, 3iHP, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France. a_buisson@hotmail.fr. 7. M2iSH, Inserm U1071, 3iHP, USC-INRA 2018, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. a_buisson@hotmail.fr.
Abstract
BACKGROUND: Medical therapy efficacy remains controversial in stricturing Crohn's disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making. AIM: To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn's disease. METHODS: In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI). RESULTS: Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn's disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37-11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01-1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04-1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64-19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40-0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03-0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01-0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005-0.97], p = 0.047) were associated with short-term clinical failure. CONCLUSION: Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn's disease.
BACKGROUND: Medical therapy efficacy remains controversial in stricturing Crohn's disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making. AIM: To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn's disease. METHODS: In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI). RESULTS: Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn's disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37-11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01-1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04-1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64-19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40-0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03-0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01-0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005-0.97], p = 0.047) were associated with short-term clinical failure. CONCLUSION: Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn's disease.
Authors: Anthony Buisson; Constance Hordonneau; Marion Goutte; Julien Scanzi; Felix Goutorbe; Thomas Klotz; Louis Boyer; Bruno Pereira; Gilles Bommelaer Journal: Dig Liver Dis Date: 2015-11-22 Impact factor: 4.088
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: F Zorzi; S Zuzzi; S Onali; E Calabrese; G Condino; C Petruzziello; M Ascolani; F Pallone; L Biancone Journal: Aliment Pharmacol Ther Date: 2012-04-22 Impact factor: 8.171
Authors: C Hordonneau; A Buisson; J Scanzi; F Goutorbe; B Pereira; C Borderon; D Da Ines; P F Montoriol; J M Garcier; L Boyer; G Bommelaer; V Petitcolin Journal: Am J Gastroenterol Date: 2013-11-19 Impact factor: 10.864
Authors: Iago Rodríguez-Lago; Javier Del Hoyo; Alexandre Pérez-Girbés; Alejandro Garrido-Marín; María José Casanova; María Chaparro; Agnès Fernández-Clotet; Jesús Castro-Poceiro; María José García; Sara Sánchez; Rocío Ferreiro-Iglesias; Iria Bastón; Marta Piqueras; Lola Esteba I Bech de Careda; Raquel Mena; Cristina Suárez; Joaquín Poza Cordón; Alicia López-García; Lucía Márquez; Maite Arroyo; Erika Alfambra; Mónica Sierra; Noelia Cano; Pedro Delgado-Guillena; Víctor Morales-Alvarado; Juan Carlos Aparicio; Iván Guerra; Carolina Aulló; Olga Merino; Laura Arranz; María Araceli Hidalgo; Jordina Llaó; Rocío Plaza; Gema Molina; Paola Torres; Pablo Pérez-Galindo; María Giselle Romero; Claudia Herrera-deGuise; Edisa Armesto; Francisco Mesonero; Santiago Frago-Larramona; José Manuel Benítez; Marta Calvo; María Del Carmen López Martín; Ainara Elorza; Alejandro Larena; Elena Peña; María Del Carmen Rodríguez-Grau; Jaime de Miguel-Criado; Belén Botella; José Antonio Olmos; Laura López; Urko Aguirre; Javier P Gisbert Journal: United European Gastroenterol J Date: 2020-07-28 Impact factor: 4.623
Authors: Fotios S Fousekis; Ioannis V Mitselos; Kostas Tepelenis; George Pappas-Gogos; Konstantinos H Katsanos; Georgios D Lianos; Francesco Frattini; Konstantinos Vlachos; Dimitrios K Christodoulou Journal: J Clin Med Date: 2022-04-23 Impact factor: 4.964